Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients

T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer patients who had progressed to taxanes and trastuzumab. We have...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy-Werbin, Max, Quiroga, Vanesa, Cirauqui, Beatriz, Romeo, Margarita, Felip, Eudald, Teruel, Iris, Garcia, Juan Jose, Erasun, Carlos, España, Sofia, Cucurull, Marc, Montprade, Elisabeth, Pardo, Juan Carlos, Carballo, Dania, Velarde, Jose Maria, Margeli, Mireia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726763/
https://www.ncbi.nlm.nih.gov/pubmed/31484985
http://dx.doi.org/10.1038/s41598-019-49251-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726763/
https://www.ncbi.nlm.nih.gov/pubmed/31484985
http://dx.doi.org/10.1038/s41598-019-49251-5

Ejemplares similares